Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIO-CHANGE LTD. currently manages a portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action across its active filings. This single pending office action is being handled by 1 distinct examiner, indicating a highly concentrated prosecution focus at this stage.
The prosecution activity is limited to 1 distinct art unit. JONES-FOSTER, ERICA NICOLE is identified as the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending office action. The alignment of 1 pending office action with 1 distinct examiner suggests that every active matter is currently under the review of a single individual.
Practitioners should note that the concentration in 1 distinct art unit simplifies the jurisdictional landscape for this portfolio. With only 1 distinct examiner involved, the outcomes for the current pending office actions are entirely dependent on the specific tendencies of JONES-FOSTER, ERICA NICOLE. This singular focus within Biotechnology & Pharmaceuticals allows for a very specific prosecution strategy tailored to the requirements of the identified art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572312 | MICROPARTICLE TISSUE SCAFFOLD COMPOSITIONS, APPARATUSES, METHODS OF PREPARATION, AND USES THEREOF | JONES-FOSTER, ERICA NICOLE | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572312 | MICROPARTICLE TISSUE SCAFFOLD COMPOSITIONS, APPARATUSES, METHODS OF PREPARATION, AND USES THEREOF | JONES-FOSTER, ERICA NICOLE | 14d |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572312 | MICROPARTICLE TISSUE SCAFFOLD COMPOSITIONS, APPARATUSES, METHODS OF PREPARATION, AND USES THEREOF | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103§112Other | Final Rejection | 14d | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial